Observational study finds monocyte aging associated with depression symptoms in women living with HIV — Evidence Review
Published in The Journals of Gerontology: Series A, by researchers from NYU Rory Meyers College of Nursing, Yale University, Johns Hopkins University, Albert Einstein College of Medicine, University of Miami Miller School of Medicine, Stroger Hospital of Cook County Health System, University of Alabama at Birmingham, UNC Chapel Hill, Downstate Health Sciences University, Georgetown University, Emory University
Researched by
— the AI search engine for science
Table of Contents
Scientists have found that the biological aging of certain immune cells—specifically, monocytes—may serve as a blood-based indicator for nonphysical symptoms of depression, such as hopelessness and loss of pleasure. Related research broadly supports the link between immune cell changes and depression, although most prior studies have focused on broader biomarker panels rather than cell-type-specific aging; this study by the NYU Rory Meyers College of Nursing adds novel insight by linking monocyte aging to emotional, but not physical, symptoms.
- Multiple studies have demonstrated that blood-based biomarkers—including multi-analyte panels and specific immune cell markers—can distinguish major depressive disorder (MDD) patients from controls with reasonable accuracy, highlighting the potential for objective diagnostic tools, though not all focus on monocyte aging specifically 1 2 3.
- Research has consistently associated immune system dysfunction, particularly in monocytes and T cells, with depression severity and symptom profiles, supporting the biological plausibility of the new study’s findings 6 7 8 9.
- Prior work suggests that while some biomarkers (like BDNF) change with treatment, they do not reliably correlate with depression severity or treatment response, underscoring the need for more specific or nuanced markers such as those proposed in the current study 4 5.
Study Overview and Key Findings
Depression remains one of the most prevalent mental health conditions globally, yet objective, biological markers for its diagnosis are lacking. Current clinical assessments rely largely on self-reported symptoms, which can be heterogeneous and influenced by co-existing physical illnesses. This study is significant because it explores whether the biological aging of particular immune cells—monocytes—can serve as an objective indicator for the emotional and cognitive symptoms of depression, offering promise for more precise and earlier detection, especially in high-risk populations such as women living with HIV.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | NYU Rory Meyers College of Nursing, Yale University, Johns Hopkins University, Albert Einstein College of Medicine, University of Miami Miller School of Medicine, Stroger Hospital of Cook County Health System, University of Alabama at Birmingham, UNC Chapel Hill, Downstate Health Sciences University, Georgetown University, Emory University |
| Journal Name | The Journals of Gerontology: Series A |
| Authors | Nicole Beaulieu Perez, Ke Xu, Yanxun Xu, Lang Lang, Kathryn Anastos, Maria L Alcaide, Mardge Cohen, Sadeep Shrestha, Andrew Edmonds, Jacquelyn Meyers, Seble Kassaye, Igho Ofotokun, Gypsyamber D’Souza, Bradley Aouizerat, Leah H Rubin |
| Population | Women living with HIV and without the infection |
| Sample Size | 440 participants |
| Methods | Observational Study |
| Outcome | Biological aging of immune cells and depression symptoms |
| Results | Monocyte aging linked to nonphysical depression symptoms, not physical ones. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus paper database, which includes over 200 million research papers. The following queries were used to identify relevant literature:
- blood test depression diagnosis
- monocyte aging depression symptoms
- nonphysical symptoms depression measurement
Summary Table of Topics and Key Findings
| Topic | Key Findings |
|---|---|
| Can blood-based biomarkers objectively diagnose depression? | - Multi-assay serum tests and transcriptomic biomarker panels can distinguish MDD patients from controls with high sensitivity and specificity, though further validation is needed 1 2 3. - Some biomarkers, like BDNF, change with treatment but do not reliably reflect depression severity or treatment response 4. |
| How are monocyte and immune cell changes involved in depression? | - Depression is associated with overexpression of monocyte-related proinflammatory cytokines and chemokines, and deficiencies in T and NK cell function 6 7. - Monocyte gene expression profiles and aging markers are elevated in subsets of depressed patients, particularly those over 28 years or with certain risk profiles 8 9. |
| Do immune-related biomarkers capture specific depression symptoms? | - Monocyte activation and immune aging are more strongly associated with emotional and cognitive symptoms, rather than somatic symptoms, of depression 9 11. - Some blood-based markers (e.g., miR-144-3p) may predict specific symptom clusters or treatment response, but results are mixed regarding which symptoms are most closely linked to biological measures 5 11. |
| What is the clinical utility and limitation of blood-based depression tests? | - Multi-marker blood tests have demonstrated robust performance in research settings, but broader application requires validation across diverse populations and consideration of confounders like gender and BMI 1 3. - Objective biomarkers could complement subjective assessments, but no single marker has yet achieved clinical adoption for diagnosing or subtyping depression 1 2 3 4. |
Can blood-based biomarkers objectively diagnose depression?
A growing body of research supports the potential for blood-based panels, including serum proteins and transcriptomic markers, to identify major depressive disorder with high sensitivity and specificity. However, most biomarker panels tested to date have focused on a broad array of markers rather than the specific aging of immune cell subtypes as explored in the new study. These findings indicate that objective diagnosis is possible, but the translation into clinical practice requires further validation and refinement.
- Multi-analyte serum-based tests (e.g., MDDScore) report sensitivities and specificities above 90% in differentiating MDD from controls, but require validation in larger, more diverse cohorts 1 3.
- Blood transcriptomic panels also show discriminative power and may track response to cognitive behavioral therapy, but the markers often remain altered even after remission 2.
- Individual markers such as BDNF are less promising as diagnostic tools, given their lack of correlation with symptom severity or treatment outcomes 4.
- The new study complements these findings by proposing a cell-type-specific marker (monocyte aging) rather than a broad biochemical panel.
How are monocyte and immune cell changes involved in depression?
Existing studies have linked immune system alterations—particularly involving monocytes and T cell subsets—to depression. Inflammatory activation, premature immune cell aging ("inflammaging"), and altered gene expression profiles are observed in depressed patients, especially in certain subgroups. The current study advances this line of research by directly linking monocyte aging to specific depressive symptoms rather than to depression diagnosis more generally.
- Depression is associated with increased proinflammatory cytokine expression by monocytes 6.
- Deficiencies in T regulatory and NK cell function, alongside inflammatory monocyte activation, are commonly seen in MDD 7.
- Monocyte gene expression reflecting aging and inflammation is especially pronounced in older or trauma-exposed depressed patients 8 9.
- These immune changes may underlie both the pathophysiology and symptom heterogeneity of depression.
Do immune-related biomarkers capture specific depression symptoms?
While most biomarker research focuses on MDD diagnosis, some evidence suggests that immune markers are more closely associated with emotional and cognitive (nonphysical) symptoms than with somatic complaints. This aligns with the new study’s finding that monocyte aging correlates with symptoms such as hopelessness and anhedonia, but not with fatigue or appetite change.
- Monocyte immune activation is particularly elevated in depressed patients with emotional/cognitive symptoms, and less so in those with primarily somatic symptoms 9 11.
- Emotional and cognitive symptoms are more predictive of depression diagnosis in primary care populations than somatic symptoms 11.
- Certain blood-based markers (e.g., miR-144-3p) may also reflect or predict symptom clusters or treatment response, though evidence is not uniform 5.
- The specificity of immune aging markers for nonphysical symptoms is a novel contribution of the current study.
What is the clinical utility and limitation of blood-based depression tests?
Although multi-marker blood tests have shown promise for identifying depression in research settings, their clinical adoption remains limited by issues of reproducibility, population diversity, and specificity for depression subtypes. The new study’s focus on a cell-type-specific marker may help refine the clinical utility of blood-based tests, but further research is needed to determine their applicability across settings and populations.
- The MDDScore panel, especially with demographic adjustments, is among the most rigorously validated, yet has not seen widespread clinical use 1 3.
- Biomarkers such as BDNF, while altered in depression and responsive to treatment, do not correlate with symptom severity or outcomes, limiting their utility 4.
- Objective biomarkers are seen as complementary to, rather than replacements for, subjective assessments 1 2 3.
- The new study underscores the need for markers that are both biologically meaningful and symptom-specific.
Future Research Questions
Further research is needed to clarify the potential for immune cell aging markers in depression diagnosis and management, to validate these findings across populations, and to explore their implications for personalized treatment. Key questions for future investigation include:
| Research Question | Relevance |
|---|---|
| Can monocyte epigenetic aging predict depression in diverse populations? | The current study focused on women, many living with HIV; validation in other genders, ages, and comorbidity profiles is needed for generalizability 1 2 3 9. |
| Do monocyte aging markers change with depression treatment? | Understanding whether these biological markers respond to therapy could inform their utility for monitoring treatment response, as seen with other biomarkers like BDNF 2 4. |
| Are monocyte aging biomarkers specific to nonphysical depression symptoms? | Further studies could clarify whether these markers uniquely track emotional/cognitive symptoms versus somatic symptoms, enhancing diagnostic precision 9 11. |
| How do other immune cell types contribute to depression biomarkers? | Investigating the roles of T cells, NK cells, and other immune populations may reveal additional or complementary markers for depression subtypes 6 7 8. |
| Can blood-based biomarkers guide personalized antidepressant selection? | Exploring how biological profiles predict treatment response could help tailor therapies and improve outcomes for individuals with depression 2 3 5. |
This research highlights the potential for monocyte aging markers to serve as objective indicators for nonphysical symptoms of depression, supporting a more nuanced understanding of the biological underpinnings of mental health conditions. While the findings align with previous work on immune dysfunction in depression, further investigation will be essential to establish clinical applications and to ensure that new biomarkers are robust, specific, and broadly applicable.